Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Ocugen Inc (OCGN)

Ocugen Inc (OCGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,498,620
  • Shares Outstanding, K 198,756
  • Annual Sales, $ 40 K
  • Annual Income, $ -21,820 K
  • 60-Month Beta 4.47
  • Price/Sales 35.12
  • Price/Cash Flow N/A
  • Price/Book 12.69
Trade OCGN with:

Options Overview

Details
  • Implied Volatility 161.03%
  • Historical Volatility 76.14%
  • IV Percentile 41%
  • IV Rank 22.86%
  • IV High 359.02% on 02/26/21
  • IV Low 102.36% on 07/29/21
  • Put/Call Vol Ratio 0.13
  • Today's Volume 26,342
  • Volume Avg (30-Day) 25,432
  • Put/Call OI Ratio 0.26
  • Today's Open Interest 282,791
  • Open Int (30-Day) 229,110

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.04
  • Number of Estimates 3
  • High Estimate -0.04
  • Low Estimate -0.04
  • Prior Year -0.07
  • Growth Rate Est. (year over year) +42.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.82 +10.54%
on 08/18/21
8.75 -13.83%
on 09/13/21
+0.48 (+6.80%)
since 08/16/21
3-Month
6.11 +23.40%
on 07/15/21
9.35 -19.36%
on 08/10/21
+1.03 (+15.82%)
since 06/16/21
52-Week
0.25 +2,914.79%
on 11/02/20
18.77 -59.83%
on 02/08/21
+7.20 (+2,142.05%)
since 09/16/20

Most Recent Stories

More News
Do Options Traders Know Something About Ocugen (OCGN) Stock We Don't?

Investors need to pay close attention to Ocugen (OCGN) stock based on the movements in the options market lately.

OCGN : 7.54 (+0.13%)
OCUGEN INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Ocugen, Inc. - OCGN

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Ocugen, Inc. (NasdaqCM:...

OCGN : 7.54 (+0.13%)
Ocugen, Inc. to Present at Upcoming Citi and H.C. Wainwright Investment Conferences

Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19, today...

OCGN : 7.54 (+0.13%)
OCGN October 8th Options Begin Trading

Investors in Ocugen Inc saw new options become available today, for the October 8th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the OCGN options chain for the...

OCGN : 7.54 (+0.13%)
Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19,...

OCGN : 7.54 (+0.13%)
LAWSUITS FILED AGAINST OCGN, DKNG and PLL - Jakubowitz Law Pursues Shareholders Claims

NEW YORK, NY / ACCESSWIRE / August 17, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who...

OCGN : 7.54 (+0.13%)
DKNG : 59.97 (+0.22%)
PLL : 53.86 (-6.07%)
DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Ocugen, Inc. and Encourages Investors with Losses in Excess of $500,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - August 17, 2021) - , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen" or "the Company")...

OCGN : 7.54 (+0.13%)
Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Ocugen, Inc. (OCGN) Investors With Losses Exceeding $100K of Class Action

NEW YORK, NY / ACCESSWIRE / August 17, 2021 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Ocugen, Inc. ('Ocugen' or 'the Company') (NASDAQ:OCGN)...

OCGN : 7.54 (+0.13%)
OCGN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of August 17, 2021 in the Class Action Filed on Behalf of Ocugen, Inc. Limited Shareholders

New York, New York--(Newsfile Corp. - August 17, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Ocugen, Inc. (NASDAQ: OCGN) alleging that...

OCGN : 7.54 (+0.13%)
OCGN FINAL DEADLINE TODAY: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Ocugen, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 17 Deadline in Securities Class Action - OCGN

EQNX::TICKER_START EQNX::TICKER_END

OCGN : 7.54 (+0.13%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Ocugen Inc. is a clinical stage biopharmaceutical company. It is focused on discovering, developing and commercializing therapies which address rare and underserved eye diseases. The company's product pipeline consists of OCU400, OCU300, OCU100 and OCU200 which are in clinical stage. Ocugen Inc., formerly...

See More

Key Turning Points

3rd Resistance Point 7.97
2nd Resistance Point 7.77
1st Resistance Point 7.66
Last Price 7.54
1st Support Level 7.35
2nd Support Level 7.15
3rd Support Level 7.04

See More

52-Week High 18.77
Fibonacci 61.8% 11.70
Fibonacci 50% 9.51
Last Price 7.54
Fibonacci 38.2% 7.32
52-Week Low 0.25

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar